Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

INO-5150 (PSA and PSMA) +/- INO-9012 (IL-12) Immunotherapy in Biochemically Relapsed Prostate Cancer (17PD)


09 Dec 2017


Poster Discussion session


Ildiko Csiki


Annals of Oncology (2017) 28 (suppl_11): xi3-xi5. 10.1093/annonc/mdx710


I. Csiki1, N. Shore2, K. Bhatt1, M. Morrow1, K. Kraynyak1, L. Liu1, T. McMullan1, J. Lee1, B. Sachetta1, S. Rosencranz1, E. Heath3, M. Bagarazzi1

Author affiliations

  • 1 Clinical Development, Inovio Pharmaceuticals, 19464 - Plymouth Meeting/US
  • 2 Urology, Carolina Urologic Research Center, 29572 - Myrtle Beach/US
  • 3 Wayne State Research Institute, Karmanos Cancer Insitute, Detroit/US



INO-5150 (PSA and PSMA) +/- INO-9012 (IL-12) immunotherapy was administered to biochemically recurrent prostate cancer patients (pts) to demonstrate breaking tolerance and assess antigen-specific humoral and cellular immune responses for stabilization of disease progression.


Phase I, open-label, multi-center study in pts post-definitive therapy with a rising PSA after surgery and/or RT and PSA doubling time (DT)> 3 months (mos), testosterone > 150 ng/dL, no concomitant ADT and no evidence of metastases. Safety, immunogenicity and efficacy were evaluated in 4 treatment arms in 60 planned pts (A: 16, 2mg INO-5150; B: 15, 8.5 mg INO-5150; C: 15, 2mg INO-5150 + 1mg INO-9012; D: 16, 8.5mg INO-5150 + 1mg INO-9012) treated with 4 IM doses followed by electroporation on day 0, wks 3, 12 and 24 who were followed for a total of 72 Wks.


Across all cohorts, among evaluable pts, 35/58 (60%) had IFN-γ reactivity by ELISPOT. Antibody titers against PSA and PSMA were observed in 6/61 (10%) and 5/61 (8%) pts respectively. 19/50 (38%) pts across the trial had CD38 and Perforin + CD8 T cell responses with the greatest proportion in arm A, 8/14 (57%) as well as a high PD-1 expression of 68.6% in this arm at week 27. Pts with immune reactivity had dampening of % PSA rise (median: 28.0 vs 53.4, p = 0.02) compared to non-reactive pts. Myeloid derived stem cell (MDSC) assessment showed that the frequency of MDSCs is decreased in pts with >70% PSA decline compared to pts with radiographically confirmed disease progression. Median Day 0 PSADT improved from 8.2 to 19.0 months (mos) (p = 0.002) for all cohorts combined at last observation with highest numerical improvement in Cohort A (26.6 mos). 56/61 (90%) pts are metastasis free at median follow-up of 436 days (85-582). Safety summary: 11 Grade (Gr) 3 SAEs in 6 pts reported. 82% of pts had Gr 1-3 AE’s primarily related to injection site reactions.


INO-5150 +/- INO-9012 was safe and well tolerated. Data demonstrated both PSA and PSMA are immunogenic and INO-5150 induced cellular immune responses. Additional analyses and follow-up are ongoing to further elucidate the correlation of immunologic efficacy and clinical benefit that has been initially observed.

Clinical trial identification


Legal entity responsible for the study

Inovio Pharmaceuticals


Inovio Pharmaceuticals


I. Csiki, K. Bhatt, M. Morrow, K. Kraynyak, L. Liu, T. McMullan, J. Lee, B. Sachetta, S. Rosencranz, M. Bagarazzi: Employee of Inovio Pharmaceuticals. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings